Crizotinib 250MG (Crizonix)

Basic Product Information of Crizonix (Crizotinib) 250mg

How Crizonix (Crizotinib) Works

Crizonix contains Crizotinib, a selective, ATP-competitive small-molecule inhibitor of the ALK (anaplastic lymphoma kinase), ROS1, and c-MET/HGFR receptor tyrosine kinases. In certain lung cancers, chromosomal rearrangements create abnormal ALK or ROS1 fusion proteins (such as the EML4-ALK fusion) that are constitutively active, continuously signalling cancer cells to grow, divide, and survive.

Crizotinib binds to and inhibits these fusion kinases and their oncogenic variants, blocking downstream signalling pathways that promote tumour cell proliferation and survival. Because these fusion proteins are largely confined to cancer cells and drive the disease directly, Crizonix offers a highly targeted mechanism of action, making it the first FDA-approved biomarker-driven therapy for both ALK-positive and ROS1-positive metastatic NSCLC, and the only approved therapy specifically for ROS1-positive disease at the time of its approval.

Because of this precision mechanism, Crizonix is classified as a targeted therapy rather than conventional chemotherapy. It is taken as an oral capsule, twice daily, and treatment is only started after confirmation of ALK or ROS1 positivity using a validated diagnostic test.

Indications for Crizonix (Crizotinib)

Crizonix (Crizotinib) is indicated for the following conditions:

Benefits of Crizonix (Crizotinib) 250mg

How to Take Crizonix (Crizotinib)

Monitoring and Dosage Adjustments

Regular monitoring is essential throughout Crizonix treatment. Your oncologist will check liver function tests (ALT, AST, and total bilirubin) every 2 weeks during the first 2 months, then monthly and as clinically indicated. Monitoring also includes complete blood counts monthly, ECG and electrolytes in patients at risk of QT prolongation, heart rate for bradycardia, and prompt evaluation of any new or worsening respiratory symptoms suggestive of pneumonitis. Report any yellowing of the skin or eyes, breathlessness, cough, fever, vision changes, severe abdominal pain, or dizziness to your doctor immediately.

Drug Interactions and Important Information

Avoid concomitant use of Crizonix with strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, and clarithromycin) and strong CYP3A4 inducers (such as rifampicin, carbamazepine, and phenytoin), as these significantly alter Crizotinib plasma exposure. Use caution with moderate CYP3A4 inhibitors. Avoid grapefruit and grapefruit juice during treatment.

Crizonix may increase the plasma concentration of other CYP3A4 substrate medications, so caution is needed with sensitive substrates where small concentration changes could cause serious adverse reactions. Use with caution alongside other medicines known to prolong the QTc interval or slow heart rate. Women of childbearing potential should use effective contraception during treatment, and breastfeeding should be avoided during treatment and for 45 days after the final dose. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Crizonix.

Side Effects and Precautions

Who Should Use Crizonix (Crizotinib)?

Crizonix is suitable for adult patients diagnosed with ALK-positive or ROS1-positive metastatic Non-Small Cell Lung Cancer, confirmed by an approved diagnostic test, whether as first-line therapy or after prior treatment. It is also used in paediatric patients aged 1 year and older with ALK-positive anaplastic large cell lymphoma or ALK-positive inflammatory myofibroblastic tumour. Crizonix is prescribed by medical oncologists and paediatric oncology specialists experienced in biomarker-guided cancer therapy. A thorough medical assessment including ALK/ROS1 testing, baseline liver and cardiac function, and vision assessment is required before initiating treatment.

Manufacturer: Beacon Pharmaceuticals Ltd.

Beacon Pharmaceuticals Ltd. is a leading pharmaceutical manufacturer based in Mymensingh, Bangladesh, and the number one oncology and specialty medicine company in the country. Beacon is the first company in Bangladesh to export cancer drugs and currently exports to Asia, Africa, Europe, and Latin America. Crizonix was introduced by Beacon as the first global generic of Crizotinib, manufactured under strict WHO-GMP, cGMP, and ISO-certified standards, offering an affordable and bioequivalent alternative to Xalkori at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Crizonix (Crizotinib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Crizonix (Crizotinib) from Mediaid Pharmacy?

Crizonix represents a landmark option in the targeted treatment of genetically-defined lung cancers. As the generic equivalent of Xalkori by Pfizer, it delivers the same active ingredient, Crizotinib, with the same proven ALK/ROS1/MET-inhibition mechanism at a dramatically more affordable price. Manufactured by the internationally trusted Beacon Pharmaceuticals Ltd. under WHO-GMP and cGMP standards, and distributed globally by Mediaid Pharmacy, Crizonix gives patients worldwide access to precision lung cancer therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Crizotinib option with worldwide delivery, Crizonix from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Crizonix (Crizotinib)